A Greek innovation and an international patent

Cretan IAMA Galenica is an innovative food supplement that contains a patented combination of essential oils from three aromatic Cretan herbs, dittany (Origanum Dictamnus), thyme (Coridothymus Capitatus) and sage (Salvia Fruticosa) in specific proportions, which do not only work cumulatively, but also synergistically, with the action of one substance enhancing and/or complementing the action of the other.

These essential oils are infused in extra virgin olive oil, in combination with vitamin D3 (cholecalciferol) that contributes to the normal functioning of the immune system.

Cretan IAMA Galenica is the fruit of long research by distinguished Greek scientists/researchers of the University of Crete who, in collaboration with the Greek pharmaceutical company Galenica, managed to utilise most efficiently the wealth of the Greek land, transforming traditional knowledge into modern scientific data.
Cretan IAMA Galenica is a patented Greek Innovation (EP 10760745.9) and has been globally recognised by the Scientific Community as the first herbal preparation with such extensive published in vitro, clinical and toxicological documentation.
Multiannual research, both in vitro and in vivo, carried out before and after the launch of Cretan IAMA Galenica, has proved its beneficial effect on the symptoms caused by viral upper respiratory infections, such as the common cold and influenza.

Cretan IAMA Galenica was initiated, researched, and produced entirely in Greece. It is a brilliant research example with international recognition, transforming traditional therapeutic practices into modern scientific data.

GOLD SUPPLEMENT AWARD 2021: best supplement for the body's defenses.

Do not exceed the recommended daily dose. Food supplements should not be used as a substitute for a balanced diet. This product is not intended for the prevention, treatment, or cure of a human disease. Consult your doctor if you are pregnant, breast-feeding, under medication or have health problems. Keep out of the reach of young children. No. EOF notification: 77100/13-07-2023. The No. Notification does not constitute a Marketing Authorization by the National Organization for Medicines (EOF).